Skip to main content
. Author manuscript; available in PMC: 2018 Apr 24.
Published in final edited form as: Pediatr Blood Cancer. 2013 Sep 9;61(2):312–318. doi: 10.1002/pbc.24762

Table I. Characteristics of the Study Population, Comparing Survivor Participants and Non-Participants.

Participants
(n = 319)
 Non-participantsa
(n = 388)
  n %c   n %c   P-Valueb
Sex
    Male 140 44 223 58 0.001
    Female 179 56 165 42
Language region
    German 238 75 290 75 0.967
    French/Italian   81 25   98 25
Migration background
    None (Swiss) 293 92 349 90 0.422
    Other countries   25   8   37 10
Education
    Primary   33 10   48 12 0.105
    Secondary   93 29 131 34
    Tertiary   59 19   48 13
    Unknown 134 42 161 41
Diagnosis (ICCC-3)
    I Leukemia 115 36 121 31 0.648
    II Lymphoma   59 18   81 21
    III CNS tumor   38 11   62 16
    IV Neuroblastoma     8   4   12   5
    V Retinoblastoma     5   2     9   2
    VI Renal tumor   21   6   19   5
    VII Hepatic tumor     1   1     2   1
    VIII Bone tumor   22   7   23   6
    IX Soft tissue sarcoma   20   6   18   5
    X Germ cell tumor     9   3   17   3
    XI and XII Other tumord   8   2   5   1
    Langerhans cell histiocytosis   13   4   19   4
Surgery
    No   95 30   99 26 0.206
    Yes 224 70 289 74
Chemotherapy
    No   47 15   82 21 0.043
    Yes 272 85 306 79
Radiotherapy
    No radiotherapy 195 61 260 67 0.741
    Body and limbs radiation   76 24   65 17
    Cranio-spinal radiation   48 15   63 16
Bone marrow transplantation
    No 302 95 363 94 0.533
    Yes   17   5   25   6
Relapse
    No 281 88 354 91 0.168
    Yes   38 12   34   9
Reported late-effects
    No 185 59 249 67 0.026
    Yes 130 41 123 33
Treating clinic
    University clinic 239 75 290 75 0.956
    Cranio-spinal radiation   80 25   98 25
Participants
(n = 319)
 Non-participantsa
(n = 388)
Mean SD Mean SD P-Valuee
    Age at study  21.3 4.1  21.7 3.8 0.852
    Age at diagnosis    8.9 4.7    8.9 4.5 0.512
    Time since diagnosis  12.5 3.8  12.8 3.6 0.857

Note Percentages are based upon available data for each variable. CNS, Central Nervous System; ICCC-3, International Classification of Childhood Cancer—Third Edition.

a

Non-participants include: 375 survivors who did not respond, 13 who refused to participate (Supplemental Figure 1)

b

P-Value calculated from Chi-square statistics comparing survivor participants and survivor non-participants

c

Column percentages are given

d

Other malignant epithelial neoplasms, malignant melanomas and other or unspecified malignant neoplasms

e

P-Value calculated on two-sample mean-comparison test (t-test).